Sintilimab and Lenalidomide as a Treatment for CAEBV a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Latest Information Update: 05 Aug 2022
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Sintilimab (Primary)
- Indications Epstein-Barr virus infections
- Focus Therapeutic Use
- 21 Aug 2020 New trial record